The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.
Srdan Verstovsek
Research Funding - AstraZeneca; Bristol-Myers Squibb; Celgene; Cell Therapeutics; Geron; Gilead Sciences; Incyte; Lilly; Novartis; NS Pharma; Promedior
Ruben A. Mesa
Research Funding - Genentech; Incyte; Promedior
Lynda M. Foltz
Research Funding - Promedior
Vikas Gupta
Consultant or Advisory Role - Incyte; Novartis
Honoraria - Incyte; Novartis
Research Funding - Incyte; Novartis; Promedior
John Mascarenhas
Research Funding - Incyte; Novartis
Ellen K. Ritchie
Research Funding - Novartis; Promedior; Sanofi
Ronald Hoffman
Research Funding - Incyte; Novartis; Promedior
Richard T. Silver
Research Funding - Incyte; Novartis; Promedior
Wan-Jen Hong
No relevant relationships to disclose
Marina Kremyanskaya
No relevant relationships to disclose
Elizabeth G. Trehu
Employment or Leadership Position - Promedior
Stock Ownership - Promedior
Hagop M. Kantarjian
No relevant relationships to disclose
Jason R. Gotlib
Research Funding - Incyte; Sanofi